538 related articles for article (PubMed ID: 33718188)
1. Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Wong KK; Hassan R; Yaacob NS
Front Oncol; 2021; 11():624742. PubMed ID: 33718188
[TBL] [Abstract][Full Text] [Related]
2. NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.
Griffiths EA; Srivastava P; Matsuzaki J; Brumberger Z; Wang ES; Kocent J; Miller A; Roloff GW; Wong HY; Paluch BE; Lutgen-Dunckley LG; Martens BL; Odunsi K; Karpf AR; Hourigan CS; Nemeth MJ
Clin Cancer Res; 2018 Mar; 24(5):1019-1029. PubMed ID: 28947565
[No Abstract] [Full Text] [Related]
3. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.
Nahas MR; Stroopinsky D; Rosenblatt J; Cole L; Pyzer AR; Anastasiadou E; Sergeeva A; Ephraim A; Washington A; Orr S; McMasters M; Weinstock M; Jain S; Leaf RK; Ghiasuddin H; Rahimian M; Liegel J; Molldrem JJ; Slack F; Kufe D; Avigan D
Br J Haematol; 2019 May; 185(4):679-690. PubMed ID: 30828801
[TBL] [Abstract][Full Text] [Related]
4. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.
Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Blagitko-Dorfs N; Ford LA; Naqash R; Lübbert M; Karpf AR; Nemeth MJ; Griffiths EA
Oncotarget; 2016 Mar; 7(11):12840-56. PubMed ID: 26883197
[TBL] [Abstract][Full Text] [Related]
5. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Daver N; Boddu P; Garcia-Manero G; Yadav SS; Sharma P; Allison J; Kantarjian H
Leukemia; 2018 May; 32(5):1094-1105. PubMed ID: 29487386
[TBL] [Abstract][Full Text] [Related]
6. Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Daher-Reyes GS; Merchan BM; Yee KWL
Expert Opin Investig Drugs; 2019 Oct; 28(10):835-849. PubMed ID: 31510809
[No Abstract] [Full Text] [Related]
7. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L
Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
[TBL] [Abstract][Full Text] [Related]
9. The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.
Wolff F; Leisch M; Greil R; Risch A; Pleyer L
Cell Commun Signal; 2017 Mar; 15(1):13. PubMed ID: 28359286
[TBL] [Abstract][Full Text] [Related]
10. Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype.
Kang S; Wang L; Xu L; Wang R; Kang Q; Gao X; Yu L
Oncogene; 2022 Oct; 41(42):4696-4708. PubMed ID: 36097193
[TBL] [Abstract][Full Text] [Related]
11. Decitabine enhances targeting of AML cells by CD34
Cany J; Roeven MWH; Hoogstad-van Evert JS; Hobo W; Maas F; Franco Fernandez R; Blijlevens NMA; van der Velden WJ; Huls G; Jansen JH; Schaap NPM; Dolstra H
Blood; 2018 Jan; 131(2):202-214. PubMed ID: 29138222
[TBL] [Abstract][Full Text] [Related]
12. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia.
Goswami M; Gui G; Dillon LW; Lindblad KE; Thompson J; Valdez J; Kim DY; Ghannam JY; Oetjen KA; Destefano CB; Smith DM; Tekleab H; Li Y; Dagur P; Hughes T; Marté JL; Del Rivero J; Klubo-Gwiezdzinksa J; Gulley JL; Calvo KR; Lai C; Hourigan CS
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017151
[TBL] [Abstract][Full Text] [Related]
14. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L
Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675
[TBL] [Abstract][Full Text] [Related]
15. Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia.
Sorrentino VG; Thota S; Gonzalez EA; Rameshwar P; Chang VT; Etchegaray JP
Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358067
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
Liu B; Guo Y; Deng L; Qiao Y; Jian J
Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.
Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Karbach J; Nemeth MJ; Taverna P; Karpf AR; Griffiths EA
Leuk Res; 2014 Nov; 38(11):1332-41. PubMed ID: 25260825
[TBL] [Abstract][Full Text] [Related]
19. The use of hypomethylating agents in hematologic malignancies: treatment preferences and results.
Serin I; Dogu MH
Int J Hematol Oncol; 2021 Dec; 10(4):IJH37. PubMed ID: 35295753
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of Myelodysplastic Syndrome: You Can Run, but You Can't Hide.
Fuchs EJ
Clin Cancer Res; 2018 Mar; 24(5):991-993. PubMed ID: 29284705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]